New hope for lymphoma patients: drug combo shows promise in phase 3 trial
NCT ID NCT05051891
First seen Apr 09, 2026 · Last updated Apr 24, 2026 · Updated 3 times
Summary
This study tested whether adding the drug orelabrutinib to standard chemotherapy (R-CHOP) works better than chemotherapy alone for people with untreated mantle cell lymphoma. Only 3 patients took part. The main goal was to see if the combination delays cancer growth. This is a disease-control approach, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT-NAЇVE MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Province Cancer Hospital
Hefei, Anhui, 230009, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100143, China
-
Guangzhou First People's Hospital
Guangzhou, Guangdong, 510180, China
-
Henan Tumor Hospital
Zhengzhou, Henan, 450008, China
-
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300052, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Guangxi Medical University
Guangxi, Nanning, 530021, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 3300008, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, 450052, China
-
The First Hospital of China Medical University
Shenyang, Liaojing, 110001, China
-
The First Hospital of Jilin University
Changchun, Jilin, 130021, China
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 50011, China
-
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, 300060, China
-
Tumor in Hunan Province
Hunan, Changsha, 410013, China
-
West China Hospital,Sichuan University
Chengdu, Sichuan, 610041, China
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
he First Affiliated Hospital of Zhengjiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.